Skip to content
DataLookout
Menu

NCT05764538

DAOIB for the Treatment of Brain Fog

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jun 2026 to Jun 2027
    • Eligibility criteria expanded, about 11 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Secondary endpoints: details revised at 7 of 7 entries
  2. Notable Primary and study completion dates: Feb 2025 to Jun 2026v3
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24
Timeframe: week 0, 8, 16, 24

Secondary (7)

Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24
Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 8, 16 and 24
Change from baseline in Quality of life score at week 8, 16 and 24
Change from baseline of 17-item Hamilton Rating Scale for Depression
Change from baseline of Hamilton Anxiety Rating Scale
Show 2 moreShow less
Change from baseline of Perceived Stress Scale
Change from baseline in the score of a battery of additional cognitive tests

Arms and interventions

DAOIBExperimental

Drugs: DAOIB

Sites

1 site in 1 country

  • Kaohsiung Chang Gung Memorial HospitalKaohsiung City, Taiwan